ReviewRSC advances2023
MXene-based composites against antibiotic-resistant bacteria: current trends and future perspectives.
Review in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 48 citations in OpenAlex.
- MXene-Based MnZnO Nanocomposites for Enhanced Antibacterial Activity and Cutaneous Wound Healing.Applied biochemistry and biotechnology · 2026Article
- Electron Beam-Irradiated g-CGels (Basel, Switzerland) · 2026Article
- Biocompatibility and immunomodulation of MXenes for targeted delivery of bioactive agents and drugs.Bioactive materials · 2026Review
- Advances of MXene in Detection and Sterilization of Foodborne Pathogens.Foods (Basel, Switzerland) · 2025Review
- Synthesis and biocompatibility studies of 2D molybdenum carbide (MXene) nanosheets and their potential uses.Nanomedicine (London, England) · 2025Article
- Staphylococcal Drug Resistance: Mechanisms, Therapies, and Nanoparticle Interventions.Infection and drug resistance · 2025Review
- NHHeliyon · 2024Article
- MXene-based composites in smart wound healing and dressings.Nanoscale advances · 2024Review
- Environmental implications of metal-organic frameworks and MXenes in biomedical applications: a perspective.RSC advances · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, finding novel nanomaterial-based strategies to combat bacterial resistance is an important field of science. MXene-based composites have shown excellent antimicrobial potential owing to their fascinating properties such as excellent photothermal effects, highly active sites, large interlayer spacing, unique chemical structures, and hydrophilicity; they have great potential to damage the bacterial cells by rupturing the bacterial cell membranes, enhancing the permeability across the membrane, causing DNA damages, reducing the metabolic activity, and generating oxidative stress. After inserting into or attaching on the surface of pathogenic bacteria, these two-dimensional structures can cause bacterial membrane disruption and cell content leakage owing to their sharp edges. Remarkably, MXenes and their composites with excellent photothermal performance have been studied in photothermal antibacterial therapy to combat antibiotic-resistant bacteria and suppress chronic wound infections, thus providing new opportunities for multidrug-resistant bacteria-infected wound healing. But, details about the possible interactions between MXene-based nanosystems and bacterial cell membranes are rather scarce. Also, the mechanisms of photothermal antibacterial therapy as well as synergistic tactics including photothermal, photodynamic or chemo-photothermal therapy still need to be uncovered. This review endeavors to delineate critical issues pertaining to the application of MXene-based composites against antibiotic-resistant bacteria, focusing on their photocatalytic inactivation, physical damage, and photothermal antibacterial therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.